Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Pomalidomide Pomalyst 2 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Pomalidomide Pomalyst 4 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Raloxifene Hydrochloride Evista 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Panobinostat Farydak 20 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Abemaciclib Verzenio 150 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Abemaciclib Verzenio 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA ixazomib Ninlaro 3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Estradiol Estrace 1 mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Dabrafenib Tafinlar 75 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.